News and Press Releases
Get Involved Cystic Fibrosis Foundation Awards 2023 Impact Grants

To date, the CF Foundation has funded more than $1 million to programs created by and for the CF community.

| 5 min read
Our Research Approach CF Foundation Invests Up to $2 Million in Nosis Bio for Potential Gene Therapy Delivery Technology

Nosis Bio, an inaugural winner of the Foundation’s Golden Ticket Competition, receives funding to further explore design of novel ligands, which are specialized molecules that could help more precise targeting of relevant cells in the lung. 

| 3 min read
Advocacy | Antibiotics Adult with CF Provides Testimony at Congressional Hearing on the Impact of Antimicrobial Resistance 

Melanie Lawrence, an adult with cystic fibrosis, was selected to testify before a Senate Health, Education, Labor and Pensions subcommittee regarding the impact of antimicrobial resistance on patients who face heightened risk of infections, like those with CF.

| 3 min read
Advocacy | Our Advocacy Work Teens Advocate on Capitol Hill During the Foundation’s 15th Annual Teen Advocacy Day

More than 60 teens from across the country — almost half of whom live with cystic fibrosis — advocated for support of the PASTEUR Act.

| 3 min read
Our Advocacy Work CF Foundation Urges Congress to Prioritize Patients in PBM Reform

Centering the patient experience is the only way to successfully reform pharmacy benefit manager practices

| 4 min read
Our Research Approach CF Foundation Provides Up to $3.9M to TB Alliance to Further Develop an NTM Drug

The Cystic Fibrosis Foundation is providing additional funds to TB Alliance to advance the development of a compound that could be used to treat infections caused by nontuberculous mycobacteria.

| 2 min read
Our Advocacy Work CF Foundation Advocates to Protect Needs of People With CF in Post-Pandemic Medicaid Redeterminations

Medicaid beneficiaries are encouraged to update their information with Medicaid to ensure continued coverage.

| 5 min read
CFTR Modulators FDA Approves Kalydeco for Infants as Young as 1 Month

The U.S. Food and Drug Administration approved Kalydeco® (ivacaftor) for infants as young as 1 month who have at least one copy of 97 mutations that have proven to be responsive to Kalydeco.

| 4 min read
About the CF Foundation | Our Advocacy Work Organizations Focused on Fight Against Superbugs Celebrate Reintroduction of the PASTEUR Act

Groups urging need for revitalizing antimicrobial development call for passage of the bill this year

| 3 min read
CFTR Modulators FDA Approves Trikafta for Children Ages 2 Through 5 Years With Certain CF Mutations

With this approval, approximately 2,250 children in the U.S. will be eligible for Trikafta® (elexacaftor/tezacaftor/ivacaftor), including more than 900 who will have access to a CFTR modulator for the first time. The Cystic Fibrosis Foundation believes it is beneficial to start people with cystic fibrosis on modulators as early as possible to help prevent lung damage and the onset of complications.

| 3 min read